Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

OMNARIS

CICLESONIDE

Standard Dose
0.05MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OMNARIS is listed in Drugs@FDA under application 022004 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength SPRAY, METERED;NASAL - 0.05MG/SPRAY Sponsor AZURITY Submission history Latest submission status date: 2019-05-08 00:00:00.

Structured Monograph

Clinical summary

Approval overview OMNARIS is listed in Drugs@FDA under application 022004 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength SPRAY, METERED;NASAL - 0.05MG/SPRAY Sponsor AZURITY Submission history Latest submission status date: 2019-05-08 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
OMNARIS (CICLESONIDE) | Drug Monograph | MedicHelpline